What started as a failed treatment for venous ulcers became one of the most influential products in professional skincare. Dr. Mitchel Goldman, co-founder of SkinMedica, tells the story of how TNS was created and why it was a "longevity" product decades before the term existed.
Dr. Ted Lain sits down with Dr. Goldman, a world-renowned cosmetic dermatologist, former ASDS president, and director of cosmetic and laser surgery at Platinum Dermatology. Dr. Goldman shares how a passing comment from Dr. Richard Fitzpatrick about the skin around a wound led to the first growth factor serum. He also talks about the hard financial realities of building a skincare company and why physician-dispensed brands that invest in research stand apart.
They also cover:
Why the full "gemish" of growth factors, secretomes, and exosomes outperforms any single ingredient
How Dr. Goldman rotates growth factor products and lets patients' results guide the choice
Pre- and post-procedure skincare, and the shift toward priming fibroblasts with topical rapamycin
Whether skin longevity needs multi-targeted or single-pathway products
Dr. Goldman's personal cautionary tale about systemic anti-aging therapies, and why he favors topicals
How a topical sodium bicarbonate made for athletes is now being studied in oncology
Why aesthetic dermatology deserves a bigger place in residency training
Questions or ideas for future episodes? Email us at inquiry@scienceofskinsummit.com. If you enjoyed this conversation, please subscribe, leave a five-star rating, and share it with a colleague.
Disclaimer: This episode is not intended to provide diagnosis, treatment, or medical advice. Content provided in this podcast is for educational purposes only. Please consult with a physician regarding any health-related diagnosis or treatment.
Podden och tillhörande omslagsbild på den här sidan tillhör
A Science of Skin Podcast. Innehållet i podden är skapat av A Science of Skin Podcast och inte av,
eller tillsammans med, Poddtoppen.